X4 Pharmaceuticals’ Post

Today, we announced positive interim data from our ongoing Phase 2 trial evaluating the safety and efficacy of our product candidate in people with #ChronicNeutropenia (CN). We also announced that we’ve started screening patients for enrollment into our pivotal Phase 3 trial, the 4WARD study, to evaluate our product candidate in people with congenital, acquired primary autoimmune, or idiopathic CN.   We’re hosting a webinar today at 8:00 am ET and will detail the interim results, feature clinical experts in the treatment of CN, and discuss the 4WARD study.   Learn more here: https://lnkd.in/eaDtEtT6 #Progress4Patients 

Thank you to all the patients, families, caregivers, and the Immune Deficiency Foundation community for visiting us at the 2024 Primary Immunodeficiency (PI) Reel Talk conference and sharing your stories. We heard loud and clear about the urgent need for early, accurate diagnosis and targeted treatments. Your stories inspire and motivate us to continue our work at X4 Pharmaceuticals in bringing innovative treatments to the PI community. We look forward to seeing you again at upcoming walks and next year’s conference. #2024PIConference 

Visit X4 at the Primary Immunodeficiency (PI) Conference taking place from June 20-22! Stop by booth #117 or #216 to speak with X4 Nurse Educator, Sondra DeVorss, RN, to learn about #WHIMsyndrome or about our soon-to-be initiated, pivotal #ChronicNeutropenia clinical trial from our Sr. Director of Patient Affairs, Karen O., RN.   Don't miss this opportunity to connect with our experts!   Learn more about the conference from the Immune Deficiency Foundation here: https://bit.ly/3KtwT4W 

Don't forget to register for our June 27th virtual investor event where we will review new clinical data on our lead product candidate from our ongoing Phase 2 trial in #ChronicNeutropenia. We are excited to include renowned experts Dr. Jean Donadieu, MD, PhD, and Dr. Peter E. Newburger, MD, who will share their insights on the interim results and the high unmet need in CN.    Register now by clicking the link here: https://bit.ly/3VuyTQu    #Progress4Patients

The road to drug development and commercialization is marked by diverse challenges and opportunities that take a broad range of expertise and #camaraderie to navigate.   Fantastic job by our #X4tizen General Counsel, Natasha Thoren, who joined leading experts to discuss critical topics impacting our industry and how we deliver medical innovation to patients. Addressing issues that span the role AI can play in drug discovery and development to the Inflation Reduction Act (IRA) to emerging trends in financing and compliance requires all of us.   Thank you Baker Tilly US and MassBio for organizing and continuing the collaboration!

On Thursday, June 27, 2024, at 8:00 am ET, we will host a virtual investor event to review new interim results from our ongoing Phase 2 clinical trial exploring the use of our lead candidate in people with chronic neutropenia. Learn more and register for the event here: https://bit.ly/3V17C6X

Today we announced that our management team will be participating in the upcoming H.C. Wainwright & Co., LLC 2nd Annual BioConnect Investor Conference, taking place on May 20th, 2024, at the Nasdaq Stock Exchange in New York City. Learn more here: https://bit.ly/4beRuWp

This week, X4 is participating in the Clinical Immunology Society (CIS) #CIS2024 conference, where we are connecting with attendees to share information about XOLREMDI™ (mavorixafor), which is now FDA approved. Come visit us at Booth 110 to learn more! #ClinicalImmunologySociety #FDAApproval #BreakThroughTherapy

We're grateful to the Immune Deficiency Foundation for their dedication to the #WHIMsyndrome community. Their efforts were vital to bringing this much-needed treatment option to those in need. Together, we're advancing innovations for people with rare diseases of the immune system and look forward to continuing our momentum in the #immunodeficiency space for years to come. We can’t thank them enough for their invaluable support and collaboration! #BreakThroughTherapy